About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide a treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes
By understanding these contributing factors, you can take proactive steps to protect your heart health while using semaglutide effectively
Veterans Study (2026): In a large veterans cohort, SGLT2i showed lower kidney failure risk, but GLP-1 RAs were more protective in moderate-risk (KFRE) patients, while SGLT2i were superior in high-risk patients
Diabetes Care 44(6):12541263
Avoid fried foods, heavy cream sauces, fast food, and anything dripping in butter or oil
Do not jab or push aggressively